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Abstract 
Read-across is a popular data gap filling technique used within analogue and category 
approaches for both regulatory and product stewardship purposes. In recent years there 
have been many efforts focused on the challenges involved in read-across development, its 
scientific justification and documentation for both chemical hazard and risk assessment 
purposes. Here, we summarise a selection of the read-across frameworks published in 
technical guidance documents or in the literature, and review their respective similarities 
and differences. There was a great deal of consensus between the different frameworks in 
terms of the general steps outlined and the similarity contexts considered although the 
terminology, decision context (chemical hazard and/or risk assessment purposes) and scope 
varied. A harmonised hybrid framework is proposed to help reconcile the common guiding 
principles and steps of the read-across process which should be helpful in expanding the 
scope and decision context of the existing frameworks. This harmonised framework is also 
intended to illustrate where generalised and systematic read-across approaches taking into 
consideration new approach methodology (NAM) information can be applied.  
Keywords 
chemical hazard and risk assessment; read-across development framework; read-across 
assessment framework; harmonised hybrid workflow; new approach methodology (NAM); 
generalised read-across (GenRA) 
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Highlights 
 Read-across development and assessment frameworks are reviewed 
 Similarities and differences of the frameworks are highlighted  
 A harmonised hybrid framework is proposed  
 Harmonised hybrid framework highlights where New Approach Methodologies 
(NAM) fit 
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Abbreviations 
(ADME) Absorption, Distribution, Metabolism, Excretion; (AOPs) Adverse Outcome 
Pathways; (AUC) Area under the Curve; (AEs) Assessment Elements; (AOs) Assessment 
Options; (BMDL) Benchmark Dose Level; (CAAT) Center for Alternative to Animal Testing; 
(Cefic-LRI) European Chemistry Industry Councilǯs Long Range Initiative; (CLP) 
Classification Labelling and Packaging regulation; (ECHA) European Chemicals Agency; 
(ECETOC) European Centre for Ecotoxicology and Toxicology of Chemicals; (EC JRC) European Commissionǯs Joint Research Centre; (EU) European Union; (EU TCNES) EU 
Technical Committee for Existing Chemicals; (EU TC C&L) EU Technical Committee for 
Classification and Labelling; (HC) High Content; High Production Volume (HPV); (HT) High 
Throughput; (IATA) Integrated Approaches to Testing and Assessment; (log D) the 
distribution coefficient; (log Kow) the log of the octanol-water partition coefficient; 
(LOAEL)Lowest Observed Adverse Effect Level; (MIE) Molecular Initiating Event; (MoA) 
Mode of Action; (MW) molecular weight; (NAM) New Approach Methodologies; (NOAEL) No 
Observed Adverse Effect Level; (OECD) Organisation for Economic Co-operation and 
Development; (pKa) the acid dissociation coefficient; (POD) Point of Departure; (PPRTVs) 
Provisional Peer Reviewed Toxicity Values; (QSARs) Quantitative Structure-Activity 
Relationships; (RAAF) Read-Across Assessment Framework; (REACH) Registration 
Evaluation Authorisation and restriction of Chemicals; (ROC) Receiver Operating 
Characteristic; (RPF) Relative Potency Factor; (RMSE)Root Mean Square Error; (SAR) 
Structure-Activity Relationship; SEURAT-1 (Safety Evaluation Ultimately Replacing Animal 
Testing); (TEF) Toxicity Equivalence Factor; (US EPA) United States Environmental 
Protection Agency; (UVCBs) Substances of unknown or variable composition, complex 
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Party on Hazard Assessment 
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1. Introduction 
1.1 Background context 
The legislative landscape particularly in Europe (e.g. Registration Evaluation Authorisation 
and restriction of CHemicals (REACH) [1], Classification Labelling and Packaging regulation 
(CLP) [2], Cosmetics Directive [3]) has stipulated that information requirements for hazard 
and risk assessment should be addressed without recourse to animal testing. As there are 
thousands of data-poor or toxicologically uncharacterised chemicals in commerce, this has 
invariably shined a light on read-across as a convenient and efficient data gap filling 
technique. Yet, this has also prompted a more critical examination of its application and 
scientific justification. Whilst read-across is traditionally anchored with conventional in vivo 
and in vitro data, concerted efforts are starting to be made to exploit high throughput (HT) 
and high content (HC) screening data as a means of substantiating biological similarity [4-8]. 
Some of these efforts are anchoring such data to key events within adverse outcome 
pathways (AOPs) [8]. More information about AOPs themselves can be found in associated 
references [9-11]. Examples of AOP informed Integrated Approaches to Testing and 
Assessment (IATA) [12] based on read-across have been developed as part of the 
Organisation for Economic Co-operation and Development (OECD) work programme under 
the auspices of the Task Force of Hazard Assessment (TFHA)1 (see 
http://www.oecd.org/chemicalsafety/risk-assessment/iata-integrated-approaches-to-
testing-and-assessment.htm for a list of case studies both published (nine as of the time of 
writing) and under review (four at the time of writing)).  
                                         
1 TFHA has since been renamed to the Working Party on Hazard Assessment (WPHA) 
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Although there is extensive technical guidance available [13-15] which describes the 
workflow of category/analogue development and associated read-across, many challenges 
still remain. The consistency in how read-across predictions are derived, the level of 
evidence required to support a read-across justification, the uncertainty or confidence in the 
underlying analogue data and the documentation required, have all impeded greater 
acceptance of read-across for regulatory purposes [16-18]. Many researchers within 
academia and government agencies, as well as chemical industries that are being regulated, 
have been actively working in an attempt to clarify the issues and overcome these challenges. 
For instance, the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) 
sponsored a task force to characterise the state of the art in read-across [19-20]. The insights 
described in the task force report [19] formed part of the discussions at an expert workshop 
organised by the European Chemicals Agency (ECHA) with active support from the European Chemistry Industry Councilǯs Long Range Initiative (Cefic-LRI) ([21]; http://cefic-
lri.org/wp-content/uploads/2014/03/ECHA-Cefic-LRI-Read-across-Workshop-
Report_171211-FINAL.pdf). ECHAǮs draft of the Read-Across Assessment Framework 
(RAAF) (https://echa.europa.eu/news-and-events/events/event-details/-
/journal_content/56_INSTANCE_DR2i/title/experts-workshop-on-read-across-
assessment-with-active-support-from-cefic-lri), a consistent set of principles for evaluating 
read-across justifications submitted under REACH, was first presented at this workshop 
prior to its initial publication in 2015 [22-23]. Elsewhere, the Center for Alternative to 
Animal Testing (CAAT) initiated a cross stakeholder workgroup including representatives 
from academia, industry and governmental agencies to facilitate read-across use. A white 
paper was published [16], and a team of ~30 experts then set about describing good read-
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across practice along with reasons related to non-acceptance by ECHA [18]. Case studies to 
illustrate the extent to which HT/HC screening data could be useful in capturing biological 
similarity in conjunction with the traditional chemical similarity approaches were also 
developed [7, 18]. Several of the most recent European Union (EU) research programmes 
have been focused on moving away from traditional animal testing – the SEURAT-1 (Safety 
Evaluation Ultimately Replacing Animal Testing) programme (http://www.seurat-1.eu/) 
was a particular example that included a significant read-across component [24]. Templates 
for structuring and reporting of read-across predictions were developed and applied to a set 
of repeated dose toxicity case studies to compare and contrast traditional read-across as well 
as the support of read-across justifications through the integration of data from the so-called 
New Approach Methodologies (NAM) ([8, 25] and references within). Further work on read-
across is also being undertaken in the on-going EU programme EU-ToxRisk (see 
http://www.eu-toxrisk.eu/). 
As a result of its widespread use supported by on-going research activities, there have been 
many efforts to refine and improve the manner in which read-across is performed and 
documented. There are several different frameworks available (both to undertake and 
evaluate read-across), described in both regulatory technical guidance and peer-reviewed 
scientific literature. For an end-user, understanding the similarities and differences of these 
different frameworks as well as their application or decision contexts represents a steep 
learning curve in and of itself. In our previous article [26], we described a generalised 
workflow for analogue and category development and illustrated where a selection of 
publicly available software tools aligned in this workflow. The intent was to help guide an 
end-user through the Ǯminefieldǯ of available tools and provide some context on where these 
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tools could be most useful depending on the decision of interest. In a similar manner, this 
article is aimed at providing a clarifying perspective on the different frameworks/workflows 
that exist to either develop category and analogue approaches or to assess their associated 
read-across justifications. A harmonised framework is also proposed to help reconcile the 
common guiding principles and steps of the read-across process which should be helpful in 
expanding the scope and decision context of the existing frameworks. This harmonised 
framework is also intended to provide context for how generalised and systematic read-
across approaches, taking into consideration new approach methodology (NAM) 
information, are evolving. Indeed, using NAM data can be an aim in itself, as such grouping 
of substances could be beneficial in other contexts of assessment not only as a part of a 
regulatory read-across assessment.  
Our earlier article [26] has already described many of the terms of reference associated with 
read-across, we only briefly highlight these for ease of comprehension. We then describe a 
handful of the available workflows including whether they are aimed at developing read-
across and/or assessing read-across. We summarise the similarities and differences of these 
different workflows to make explicit how and where these are consistent with each other. 
We also propose a harmonised hybrid workflow to reconcile the existing frameworks and 
provide a direction for how systematic read-across is evolving to include where the new 
approach methodology (NAM) approaches can and are being practically utilised. Figure 1 
provides a graphical outline of this article for ease of reading. 
2. Terms of reference 
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In brief, groups of substances with similar human health and/or environmental toxicological 
properties typically based around some concept or aspect of chemical similarity are known 
as chemical categories. A category of two substances (a target which is the substance of 
interest and a source analogue with data to read-across) is referred to as an analogue 
approach. Read-across is reserved as a term to describe one of the main data gap filling 
techniques within category or analogue approaches and can be qualitative or quantitative. 
Other data gap filling techniques include trend analysis and external Quantitative Structure-
Activity Relationships (QSARs) [as described in reference 26].  
2.1 Considerations before embarking on a read-across 
Considerations before embarking on a read-across approach have been discussed at length 
elsewhere [16, 17, 19, 20, 27]. The types of considerations vary to a degree depending on the 
decision context; e.g. the objective may be to extract chemical categories from a starting large 
inventory of substances (termed a Ǯtop-downǯ approach) or the context might be to start with 
a specific target substance and identify suitable source analogues (termed a Ǯbottom upǯ 
approach) (described in more detail in [28-29]). In this article, we focus on the Ǯbottom upǯ 
decision context, i.e. where the starting point is considering a specific target substance and 
building up an analogue or category approach from appropriate source analogues.  
Other considerations depend on the degree of uncertainty that can be tolerated in the read-
across prediction as well as the magnitude of effort and resources that can or should be 
brought to bear to address the overall decision i.e. risk-decision/safety assessment. These 
encompass the number of data gaps and for which endpoints, a plausible hypothesis for 
grouping substances together and the ease and cost of substantiating that hypothesis, as well 
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as the legitimate access to sufficient, high quality and relevant data [13, 16-17, 26]. Some of 
this information may not be known a priori but may be elucidated once a more detailed 
evaluation of the associated data for source analogues is undertaken. 
2.2 Sources of regulatory and technical guidance 
Category and analogue approaches have been in use for many years. One of the first instances 
of read-across in a regulatory context was described by Hanway and Evans (2000) of the UK 
Health and Safety Executive for human health endpoints [30]. Reviews of regulatory use of 
chemical categories and read-across were prepared as part of the OECD and European Commissionǯs Joint Research Centre (EC JRC) work programmes in preparation to the 
development of the REACH technical guidance [27-29]. The reviews revealed that technical 
guidance for categories was first developed by the United States Environmental Protection 
Agency (US EPA) in support of the US High Production Volume (HPV) Challenge Program in 
1998 [31]. The same principles were embedded into the OECD Manual for the Assessment of 
Chemicals used as part of the OECD HPV programme, specifically, Chapter 3 of the manual 
provided guidance for grouping of substances and SARs [32]. In the run up to REACH 
regulation [1], the EC JRC in collaboration with OECD developed technical guidance for 
category formation and read-across which could serve to satisfy the needs for REACH as well 
as global regulatory requirements. The OECD guidance for grouping was published in 2007 
[13]. The ECHA guidance (which is almost identical to the OECD guidance) was published 
several months later as ǲR6 QSARs and Grouping of Chemicalsǳ [15]. In 2012, ECETOC 
formed a task force to describe the state-of-the art of category approaches in order to 
provide some practical guiding principles for Industry registrants that would be of help with 
12 
 
their EU REACH dossier preparation. The ECETOC task force report (TR116) was published 
in late 2012 [19] and an executive summary from it formed one of the background papers 
for the ECHA expert workshop with active support from Cefic LRI in October 2012 [21]. 
Given the insights gained from read-across justifications prepared by industry and evaluated 
by OECD member countries, coupled with developments in Adverse Outcome Pathways 
(AOPs), the OECD established a new drafting group to revise the 2007 grouping guidance. 
The revision was published in 2014 [14] and in fact took up a number of the 
recommendations from the ECETOC report [19] as well as other publications that had been 
published in the peer reviewed literature since 2007, e.g. [33-34]. Although ECHA have not 
updated their original guidance, they have published practical guides on the use of read-
across 
(https://echa.europa.eu/documents/6362380/7127661/pg_report_readacross_en.pdf/69
860e5b-c669-4a0d-b868-72f5dba5b560), an illustrative case study 
(https://echa.europa.eu/documents/10162/13628/read_across_example_1_en.pdf), in 
addition to their read-across assessment framework (RAAF) [22-23]. 
Aside from the regulatory technical guidance, there are a number of articles in the peer 
reviewed literature that have described frameworks for how to develop read-across 
justifications. Although the needs of REACH [1], CLP [2] or the EU Cosmetics Regulation [3] 
have provided significant momentum, these other frameworks are sufficiently generic to 
serve other risk and/or safety assessment purposes. Notable examples include the 
framework for using structural reactivity, metabolic and physicochemical similarity to 
evaluate the suitability of analogues for (structure-activity relationship (SAR) based 
toxicological assessments by Wu et al [33]. This was followed up by a set of case studies 
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published by Blackburn et al [34] to illustrate the practical application of the approach. Wang 
et al [35] published a tiered surrogate approach for use in human health risk assessment 
based on the insights and experiences used within the EPAǯs process for deriving screening-
level provisional peer reviewed toxicity values (PPRTVs) for data-poor chemicals of interest 
to the EPAǯs Superfund program [https://hhpprtv.ornl.gov/]. Patlewicz et al [20] 
summarised the key insights from the ECETOC report to articulate the general 
considerations for using category approaches. They also summarised the main learnings 
from the ECHA-CEFIC LRI workshop [21] and updated the earlier paper [20] based on industriesǯ own experiences under REACH [17]. The CAAT Working Groupǯs 
recommendations and best practices were summarised by Ball et al [18] who additionally 
described some of the main shortcomings in the read-across justifications submitted to 
ECHA based on a review of the ECHA published decisions. 
In summary, there are several frameworks focused on the development of read-across 
justifications. These include the ECHA guidance [15], the OECD guidance [14], Wu et al [33], 
Wang et al [35] and Patlewicz et al [20]. These are compared and contrasted to better 
articulate their similarities and differences. 
3. Frameworks for the development of read-across  
3.1 Category/Analogue approaches as described by OECD and ECHA 
As indicated earlier, the guidance for analogue and category development was jointly 
developed by OECD and EU JRC to address REACH [1] and other regulatory frameworks at 
the same time. These include chapters that specifically describe a stepwise procedure to the 
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analogue and category approach. There are very minor variations in these stepwise 
procedures between the 2 documents, which we highlight below. 
3.1.1 ECHA (2008) Stepwise procedure to the analogue approach 
The first step in the ECHA approach [15] is to search for potential sources analogues for the 
target substance – see Figure 2. The next step is to gather data for the source analogues and 
evaluate their fitness for purpose which can be done, in part, by constructing a data matrix. 
The adequacy of the read-across is then assessed; if this is sufficient, the data gap is filled and 
the prediction is documented. If the read-across is not adequate – either additional 
analogues are searched for, or new experimental data are generated.  
3.1.2 ECHA (2008) stepwise procedure to category development ECHAǯs [15] category approach is very similar to the analogue approach (see Figure 3), save 
for an additional step that calls for a check on whether an existing regulatory category might 
already be available. If this is the case, this could be updated with new data and the category 
re-assessed to determine that it still is valid for its intended purpose. If no existing category 
is available, the procedure calls for a hypothesis to be developed to aid in the identification 
of source analogues. One other notable difference with the category approach is that an 
adequate category might not be possible to construct.  
3.1.3 OECD Stepwise approach to an analogue approach 
The procedure outlined in the OECD grouping guidance [14] differs only marginally with the 
ECHA approach in terms of the actual workflow diagram (see Figure 4). A Step 0 has been 
introduced in the approach to consider whether a target substance is a member of an existing 
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category. Step 6, which involves documenting the read-across, specifically calls for the 
justification to be documented. 
3.1.4 OECD stepwise approach to category development 
The ECHA and OECD workflows are more or less identical save for one item – the ECHA 
guidance calls for a re-assessment of an existing category if new data are available. This step 
is not explicitly captured in the OECD stepwise approach though is described in the 
associated text.  
Although the workflows are to all intents and purposes the same between the OECD [14] and 
ECHA [15], the main significant difference is the extent to which the OECD guidance 
describes how other types of data can be used in the construction of the data matrix such as 
mechanistic data anchored to key events within an AOP. Within Step 3 of the category approach ǲEvaluate available data for adequacyǳ, practical steps on how to group chemicals 
using an AOP are offered. Specific references are made to the AOP for skin sensitisation that 
was published by the OECD in 2012 [36]. 
It is important to consider these workflows in light of prior guidance. Specifically, the OECD 
[13] and ECHA [15] technical guidance, represented the first time a connection between 
QSAR approaches and categories was made. It is now well established that the underlying 
basis for both approaches is the same, but at the time these guidance documents were first 
drafted, this represented a major step forward in terms of expressly articulating their 
connection. The guidance document also sought to clearly define key terms of reference to avoid ambiguity, for example Ǯread acrossǯ (by convention written as read-across) had been 
used synonymously with what is now termed the analogue approach rather than strictly as 
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a data gap filling technique. The delineation of other data gap filling techniques was also 
expanded and extended in light of the advances made in QSAR development and its 
application for regulatory purposes beyond screening or prioritisation. The manner in which 
key information of the approach should be documented in a consistent format was also 
novel. The formats, so named reporting formats, provided a much more structured manner 
for performing and documenting the justification and rationale for the category or analogue 
approach. The concept of the reporting format was largely driven by similar formats derived 
to document QSAR models and their associated predictions [15]. The way in which the 
approaches were structured was subsequently helpful in the development of the associated 
OECD QSAR Toolbox, a tool aimed at the development, evaluation, justification and 
documentation of chemical categories [37]. 
One of the shortcomings in the OECD and ECHA guidance (which in many respects prompted 
the OECD revision) was that, as much as it described the steps of how to derive a category or 
analogue approach, it lacked sufficient information or guidance for how the approach should 
be documented and the level of justification that should be merited – for example how to 
assess the adequacy of the approach in terms of its uncertainties. At the time of development, 
there were no examples to draw from aside from the experiences of the OECD and EPA HPV 
programmes [38] and the insights derived from the use of category and QSAR approaches as 
they had been applied within the EU Technical Committees for Existing Chemicals (EU 
TCNES) or Classification and Labelling (EU TC C&L). These insights and experiences were 
drawn upon extensively in the initial drafting of the guidance and were compiled as a 
compendium of case studies [27] that were also published and cited in the guidance itself 
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[13,15]. The issue of adequacy or sufficiency of the justification is discussed in a later section 
(section 4) where we describe frameworks intended to assess read-across. 
 
3.2 Framework by Wu et al (2010) 
Wu et al [33] presented the ǲsystematic expert-driven processǳ that the Procter and Gamble 
Company uses to evaluate analogues for read-across in SAR-based toxicological assessments. 
One of the drivers for this publication was in response to some of the shortcomings the 
authors themselves had noted of the original OECD [13] and ECHA [15] guidance which they 
felt was insufficient for assessing the adequacy of source analogues i.e. the analogue 
evaluation step. The article describes a flowchart (see Figure 5) to outline the overall source 
analogue identification and evaluation process. It also describes the ranking of source 
analogues in more detail with respect to different similarity contexts. In brief, the first step 
of the overall workflow relies upon a chemistry expert(s) to review the target substance in 
conjunction with other tools/resources (such as expert systems, structure searchable 
databases, literature etc.) to devise the optimal search strategy that will take into account 
key functional groups and features and how these might impact the physicochemical, 
reactivity or metabolic profile. Based on the search performed, the results are then filtered 
to retrieve only those source analogues with relevant toxicity data. 
An assessment of the source analogues (see Figure 6) is then performed to evaluate their 
suitability on the basis of their structural, physicochemical characteristics, reactivity and 
18 
 
metabolism. For the initial search, a Tanimoto2 threshold of 0.75 is used as a default to limit 
the number of structurally similar analogues retrieved. This threshold may be modified 
depending on what is known or can be inferred about how the toxicity is driven (e.g. toxicity 
driven by a specific reaction centre). Evaluating the structural differences between the 
source analogues and the target is then performed to appreciate whether any of those 
differences would lead to a significant difference in the reactivity and toxicity anticipated. 
The practical manner in which this evaluation is performed is to evaluate: (1) the 
commonality of structural alerts (such as those contained within expert systems such as 
Derek Nexus (Lhasa Ltd)); (2) the commonality of key functional groups (that would be 
critical for driving the reactivity and sites for metabolism); (3) the commonality in position 
of double bonds and, (4) the effects of additional functional groups. This multifaceted 
evaluation would be followed by an assessment of the similarity of the physicochemical 
characteristics of the source analogues relative to the target. Parameters include the log Kow 
(the log of the octanol-water partition coefficient), molecular weight (MW), water solubility 
as well as log D (the distribution coefficient) and pKa (the acid dissociation coefficient), all 
of which Ǯmodelǯ likely bioavailability. Significant differences in the physicochemical 
parameters of the source analogues relative to the target substance are considered helpful 
in identifying or rationalising any differences observed in in vitro or in vivo toxicity studies 
[33]. The last consideration is the similarity of the metabolic profile between the target and 
source substance. The aspects considered are whether there exists the potential of the 
                                         
2 Note there are many aspects to take into account when using Tanimoto as a similarity threshold including 
the manner in which the source analogues and their inventory are characterised to enable rapid searching, as 
well as what an appropriate cut off might be. Some of these have been discussed elsewhere – see Willett et al 
[39] 
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source analogue to metabolise to the target or vice versa, whether the metabolism of source 
analogue and target diverge to different pathways or converge to similar pathways, both of 
which will have an impact on the toxicity observed. 
The considerations articulated are intended to help in performing a comprehensive 
evaluation of the suitability of the source analogues identified for a toxicity assessment.  
3.3 Tiered surrogate approach by Wang et al (2012) 
Wang et al [35] describe a tiered surrogate approach based on identifying three main types 
of potential surrogates to ultimately select the ǲbestǳ surrogate for use in a quantitative risk 
assessment. The decision tree/workflow is shown in Figure 7. 
The first step involves understanding what is known about the target substance in terms of 
its available data and any inferences that can be made about its reactivity, metabolism and 
toxicity. If no adequate repeated dose toxicity information is available for the target 
substance that allows for quantitative risk assessment, a search is made to identify 
surrogates based on structural, metabolic and toxicity considerations. For the first surrogate 
type – structural considerations include identifying structurally similar substances using the 
Tanimoto similarity index with a suitable cut off. Assessment of structurally similar 
surrogates also considers similarity in key functional groups and reactivity making use of 
structural alerts. Metabolic surrogates are the second type and include metabolic precursors, 
metabolites and (bio)degradation products/precursors. Literature data or toxicokinetic 
testing will inform this surrogate type. Potential metabolic surrogates and the target 
substance are expected to have a similar toxicological profile or mode of action that may 
result in the same ultimate toxicity at the same target organ or tissue site. The target 
20 
 
organ/tissue would also be noted at this stage especially if the target organ/tissue is known 
for the target substance. The third type of surrogate is toxicity-like – here reference is made 
to similar dose-response curves based on a toxicity equivalence factor (TEF) or relative 
potency factor (RPF). Other validated in vitro dose response data could also be considered 
to establish a potency ranking. Additionally, similarity considerations with respect to 
common target organs, toxic effects, mode of action (MoA) and group membership (as in 
well-defined chemical classes/mixtures) are taken into account when identifying this 
surrogate type. The tiered surrogate approach is reliant on the surrogates identified being 
associated with established reference /toxicity values from regulatory agencies in order to 
compile a pool of data-rich surrogate candidates with good quality repeated dose 
information, facilitating the read-across process. At this stage, physicochemical parameters 
are collected and added to the pool of information. For the target substance, an assessment, 
as far as possible, of the likely target organs/tissues is made to gauge and help compare the 
suitability of any of the surrogates identified. A weight of evidence (WOE) approach is then 
used to rank the surrogates on the basis of structural, metabolic and toxicity similarity 
considerations in order to identify the ǲbestǳ surrogate. During this approach, emphasis is 
given to biological similarity (toxicity/toxicokinetic) over structural similarity. The most 
biologically relevant surrogate with the highest similarity score and/or most health-
protective toxicity value is selected, adopting its point of departure (POD) for quantitative 
risk assessment of the target compound.  
3.4 Category approaches and read-across considerations by Patlewicz et al (2013) 
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Patlewicz et al [20] structured a workflow for category/analogue development around the 
category/analogue reporting format that is described in the OECD [14] and ECHA [15] 
guidance. Although a workflow was not structured as a graphic, a series of steps were re-
articulated as steps of read-across development in a subsequent article [17] – see Figure 8.  
In brief, the first step is to understand the decision context under consideration to determine 
the magnitude of resources that need to be applied to address the question as well as the 
amount of uncertainty that can be tolerated in the outcome. The next step seeks to identify 
the number and type of data gaps for the target substance. These will inform the way in 
which source analogues are identified (the overarching rationale3). For example, a custom 
search for an endpoint that is mechanistically well understood such as skin sensitisation will 
differ than an analogue approach based on a metabolic precursor similarity context for 
systemic toxicity endpoints. The next steps involve searching for and evaluating the source 
analogues identified. This step is critical to evaluate the validity/suitability of the analogues 
for the data gaps being filled. The evaluation covers assessment of the similarity in the 
physicochemical profile of the analogues and removal of significant outliers, assessing the 
metabolic pathway similarity of the analogues to evaluate commonality in key functional 
groups including reactivity as encoded in structural alerts. The next step involves filling the 
data gaps either by qualitative or quantitative read-across or through a trend analysis should 
a clear trend between a specific parameter and the endpoint of concern be apparent. Finally, 
an assessment of the uncertainty associated with the prediction is made – usually on the 
                                         
3 The term ǲOverarching hypothesis/rationaleǳ was used in Patlewicz et al [17] to denote the basis for grouping 
chemicals together – metabolic pathway, change in chain length etc. It was coined to describe the different 
contexts by which categories could be defined per the OECD technical guidance [14]. Here the intent is to 
provide the basis for how analogues might be practically identified which can differ if the data gap is specific 
to one endpoint vs many endpoints.  
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basis of the uncertainty relating to the similarity rationale itself as well as the uncertainty in 
the underlying data for the source analogues identified. Pradeep et al [40] provides a 
practical illustration of addressing uncertainty. Practical suggestions for the types of tools 
and resources that could be applied to address these steps are also described in the original 
manuscript [20]. 
 
Comparing the different read-across development frameworks illustrates much 
commonality in their structure, purpose and content even if the stated purpose is different 
(Table 1). 
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Table 1: Comparison of selected read-across development frameworks  
Framework ECHA [15] OECD [14] Wu et al [33] Wang et al [35] Patlewicz et al [20] 
Context REACH International 
regulatory purposes 
Product 
Stewardship 
Quantitative risk 
assessment 
Regulatory purposes 
& Product 
stewardship 
Approach Analogue/Category Analogue/Category Analogue 
 
Analogue 
 
Analogue/Category 
 
Method Aim is to fill an 
endpoint specific 
study. Focused on 
structural similarity 
as a starting point 
A generalisation of the 
ECHA approach 
Systematic 
stepwise 
evaluation of 
analogue suitability 
based on structure, 
reactivity, 
Approach is based 
on a weight of 
evidence (WOE) 
assessment from 
structure, ADME4 
and toxicity 
Approach is aimed to 
identify source 
analogues that can be 
used to address as 
many endpoints as 
appropriate, even 
                                         
4 ADME = Absorption, Distribution, Metabolism, Excretion 
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Approach is more 
hypothesis driven 
physicochemical 
and metabolism 
considerations. ǲBestǳ surrogate is 
selected from a set 
of candidates based 
on most similar 
and/or most health-
protective toxicity 
value 
though the read-
across prediction 
itself is justified on an 
endpoint per 
endpoint basis and 
some source 
analogues might be 
excluded from the 
prediction itself if 
they are not 
appropriate for 
specific endpoints of 
interest e.g. 
metabolic analogue 
excluded from 
assessment of local 
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endpoints such as 
irritation. Stepwise 
approach considering 
general 
(physicochemical, 
reactivity, 
metabolism) and 
endpoint specific 
considerations 
Terms of 
reference 
Target/Source 
Analogue 
Target/Source 
Analogue 
Substance of 
interest/Analogue 
Chemical of 
Concern/Surrogate 
Target/Source 
Analogue 
Scope Endpoint specific Endpoint specific Most 
sensitive/relevant 
endpoint – focused 
on repeated dose 
Most 
sensitive/relevant 
endpoint – focused 
on repeated dose 
Most 
sensitive/relevant 
endpoint – focused 
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and developmental 
toxicity endpoints; 
quantitative risk 
assessment 
toxicity endpoints; 
quantitative risk 
assessment. 
Surrogates must be 
associated with 
repeated dose 
toxicity data that has 
been published as 
reference/toxicity 
values. 
on repeated dose 
toxicity endpoints 
Use case Bottom up  Bottom up Bottom up Bottom up Bottom up 
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There is much similarity in the steps taken and the types of considerations brought to bear 
in these different read-across workflows. For example, all the selected frameworks propose 
an initial profiling of the target substance. This involves an analysis of the available 
information and data gaps that will direct subsequent steps in the read-across workflow 
such as the analogue search strategy and can therefore help inform the overall 
appropriateness of the read-across approach. The similarities and differences have been 
summarised and tabulated in Table 2 using the workflow described in Patlewicz et al [26] as 
an anchoring framework for convenience. 
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Table 2: Similarities and differences of selected read-across development frameworks as aligned to the framework described in 
Patlewicz et al [26] 
Framework ECHA [15] OECD [14] Wu et al [33] Wang et al [35] Patlewicz et al [20] 
Decision 
context 
REACH International 
regulatory 
purposes 
Product 
Stewardship 
Quantitative risk 
assessment 
Regulatory purposes & 
Product stewardship 
Data gap 
analysis 
Not specifically 
captured as a 
step in the 
workflow but 
implicit based 
on the 
accompanying 
Not specifically 
captured as a 
step in the 
workflow but 
implicit based 
on the 
accompanying 
Not specifically 
captured as a 
step in the 
workflow but 
discussed in the 
accompanying 
text 
 
Not specifically 
captured as a step in 
the workflow but 
discussed in the 
accompanying text 
Stated upfront in the 
workflow 
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text in the 
guidance 
text in the 
guidance 
Overarching 
rationale 
Includes 
consideration of 
existing 
categories. 
Captured in the 
reporting 
format  
Includes an 
additional step 
to check 
whether 
chemical is a 
member of an 
existing 
category. 
Captured in the 
reporting 
format 
Not explicitly 
referred to as 
an overarching 
rationale but 
captured as part 
of the initial 
profiling of the 
chemical to 
determine the 
type of custom 
search to 
identify 
analogues 
Not explicitly referred 
to as an overarching 
rationale, however 
the proposed WOE 
approach considers 
three primary 
similarity rationales 
(i.e. 1) common 
biological response, 
toxic effect or MoA, 2) 
common 
metabolite/precursor
, 3) a TEF or RPF, 
Explicitly outlined as a 
way of factoring in the 
similarity rationales as 
a means of structuring 
and informing the type 
of analogue search to 
undertake 
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which serve as 
potential hypotheses 
for facilitating the 
selection of the best 
surrogate. 
Analogue 
identificatio
n 
Heavily focused 
on structure 
search 
approaches to 
identify 
structurally 
similar 
analogues 
Heavily focused 
on structure 
search 
approaches to 
identify 
structurally 
similar 
analogues 
though 
reference is 
Custom search 
that takes into 
account 
expected 
metabolism of 
the target 
coupled with 
consideration of 
key functional 
groups, 
Informed search 
taking into account 
profile of chemical of 
concern to ensure 
that key functional 
groups, structural 
alerts or 
known/presumed 
metabolism is 
considered for the 
Unless decision context 
and data gap analysis 
inform the specificity of 
the endpoint, search 
itself is based on 
structural similarity 
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made to the 
OECD Toolbox 
to emphasise 
the ways in 
which analogue 
identification 
could be 
influenced 
based on the 
endpoint under 
consideration 
structural alerts 
encoding 
reactivity 
although search 
still relies on 
using structure 
searching 
approaches and 
setting a 
threshold for 
the similarity to 
limit the 
number of 
analogues 
identified 
identification of 
surrogate candidates. 
Search still relies on 
using structure 
searching approaches 
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Analogue 
evaluation 
Largely focused 
on the 
underlying data 
on the 
analogues and 
constructing 
this into a data 
matrix to 
facilitate an 
assessment of 
consistency and 
concordance. 
Should include 
collection of 
physicochemica
l information. 
Largely focused 
on the 
underlying data 
on the 
analogues and 
constructing 
this into a data 
matrix to 
facilitate an 
assessment of 
consistency and 
concordance. 
Should include 
collection of 
physicochemica
l information. 
A decision tree 
explicitly lays 
out the specific 
questions to 
assess the 
suitability of the 
analogues 
identified with 
respect to their 
physicochemica
l profile, 
metabolic 
profile, 
structural 
feature 
differences and 
Surrogates identified 
via structural 
similarity searches 
are filtered based on 
availability of 
reference/toxicity 
values for repeated 
dose exposure 
Surrogate data is 
collated and 
evaluated based on 
reactivity, 
physicochemical, 
metabolic and toxicity 
(similarity in mode of 
action (MoA) or 
General considerations 
of physicochemical 
characteristics, 
metabolic similarity, 
structural dissimilarity 
and reactivity potential 
are evaluated. A second 
step considers endpoint 
specific considerations 
that will impact the data 
gap filling itself 
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reactivity 
profile.  
target organ/tissue) 
considerations 
Data gap 
filling 
Evaluation of 
analogues is 
more closely 
captured in the step ǲassess the 
adequacy of the 
analogue 
approach and fill the data gapǳ 
Aspects such as 
MoA 
information, 
(Q)SAR 
Evaluation of 
analogues is 
more closely 
captured in the step ǲassess the 
adequacy of the 
analogue 
approach and 
fill the data gapǳ. 
Aspects such as 
MoA 
information, 
Not described in 
this framework – discussed in 
more detail in 
[41]; see section 
on frameworks 
for read-across 
evaluation 
The surrogate POD 
(e.g. No observed 
adverse effect level 
(NOAEL), Lowest 
observed adverse 
effect level (LOAEL), 
benchmark dose level 
(BMDL)) used to 
derive the 
reference/toxicity 
value can be carried 
forward into a 
quantitative risk 
Qualitative/Quantitativ
e read-across (often the 
most sensitive value); 
Trend analysis, External 
QSARs. 
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information, key 
functional 
groups and 
biochemical 
process are 
considered to 
evaluate the 
utility of the 
source 
analogues and 
their robustness 
in driving the 
read-across 
prediction 
(Q)SAR 
information, key 
functional 
groups and 
biochemical 
process are 
considered to 
evaluate the 
utility of the 
source 
analogues and 
their robustness 
in driving the 
read-across 
prediction 
assessment. POD 
value from the ǲbestǳ 
surrogate which is 
most similar and/or 
most health-
protective 
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Uncertainty 
assessment 
Not explicitly 
described 
Not explicitly 
described 
An uncertainty 
scale provides 
some context of 
how the 
analogues might 
then be carried 
forward into the 
toxicity 
assessment. The 
scale aligns the 
different types 
of analogues 
relative to the 
uncertainty in 
the type of read-
across that 
Not explicitly 
described 
Explicit in the workflow 
but is discussed herein 
in the section on read-
across evaluation 
frameworks 
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might be 
conducted 
based on the 
consistency and 
correspondence 
of the analogue 
data and the 
number of 
source 
analogues 
under 
consideration 
 
 
 
37 
 
4. Frameworks for Assessing Read-across 
 
There have been many efforts to explore how read-across justifications can be critically 
evaluated in order for their uncertainties to be explicitly identified and to help focus what 
practical strategies can be used to reduce those uncertainties. In this manuscript, articles and 
guidance that are more focused on evaluating read-across are denoted Ǯread-across 
assessment frameworksǯ. In many respects, this designation is arbitrary as the factors 
driving uncertainty are indirect guidance for read-across development itself. Nonetheless, 
the distinction is helpful to discriminate guidance that was specifically tailored to describe 
the steps to follow in a workflow to develop a category/analogue approach versus 
considerations to bring to bear when attempting to justify and strengthen a read-across 
prediction. Blackburn and Stuard [41] followed up from work by Wu et al [33] and Blackburn 
et al [34] to propose an assessment framework aimed at promoting greater consistency in 
read-across predictions for repeated dose and developmental toxicity endpoints [38]. Their 
article combined the SAR assessment suitability ranking described in Wu et al [33] with the 
sources of uncertainty in the source analogues themselves in order to provide qualitative 
confidence scores for any read-across performed. The framework comprises three parts. 
Part I reiterates the analogue suitability assessment described in Wu et al [33]. Part II 
comprises a series of questions to probe the consistency and quality of the data underpinning 
the source analogues identified. The types of questions address the number of studies 
addressing the endpoint for any of the source analogues; the quality of the studies for those 
source analogues; evidence in the entire source analogue set for a specific toxic effect for the 
endpoint; the concordance in endpoint specific effects and/or PODs across analogues 
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suggesting similar potency for the critical effect in the endpoint; whether the source 
analogues demonstrate low or no toxicity as well as whether the most sensitive POD was 
being used as the read-across threshold. Part III considers the consistency between analogue 
and target data across all endpoints. The question considers the concordance across the data 
in terms of the adverse effects indicating that the analogues share the same targets of 
toxicity. The overall framework considers the sources of uncertainty, namely the number of 
analogues contributing data, the robustness of the analogue dataset, the concordance of 
effects and potency, severity of critical effects in order to assign an overall uncertainty 
category and an associated default uncertainty factor. Four categories representing graded 
degrees of uncertainty were proposed. A low uncertainty category would be assigned an 
uncertainty factor of 1, whereas a low-moderate uncertainty would drive an uncertainty 
factor of 3. A moderate uncertainty would drive an uncertainty factor of 10 and finally a high 
uncertainty would mean that the use of read-across for data gap filling was not 
recommended. 
4.1 Scientific confidence considerations in read-across by Patlewicz et al (2015) 
Table 2 in Patlewicz et al [17] articulated very similar sources of uncertainty as described in 
Blackburn and Stuard [41]. The sources of uncertainty were categorised into two types – 
uncertainties associated with the underlying data of the source analogues themselves and 
uncertainties associated with the similarity rationale between the source analogues relative 
to the target substance. They tabulated strategies to reduce uncertainties dependent on the 
similarity rationale element – metabolic transformation, unspecific toxicity, specific toxicity 
or structural dissimilarities.   
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4.2 Strategy for structuring and reporting read-across by Schultz et al (2015) 
Schultz et al [25] outlined a strategy for structuring and reporting a read-across prediction. 
Four main read-across scenarios (direct acting substances with similar MoA; indirect acting 
substances with similar MoA; low or no toxicity hence not reactive or no specific MoA; and, 
structurally similar substances with different MoA) are described which in essence outline 
the types of overarching rationales by which analogues/categories might be formed. 
Assessing the validity of those source analogues is carried out with respect to different 
similarity contexts such as structure, physicochemical characteristics, toxicokinetic profile, 
abiotic/metabolic profile, toxicophore/structural alerts, mechanistic profile (same 
molecular initiating event (MIE) linked to an AOP) and in vivo toxicological responses. These 
components form one part of the overall uncertainty assessment – assessing the similarity 
of the analogues. For each similarity context, an evaluation is made to grade the data 
uncertainty underpinning each context (whether that data were modelled or experimental 
in nature) and the strength of evidence supporting that context. The evaluation is facilitated 
by a template to record each similarity context in turn, the respective gradings scaled from 
low - high and any comments. The basis for the assessment is driven by information collected 
in the data matrix structured as part of the typical read-across workflow. The other 
component of the uncertainty assessment address mechanistic relevance and the 
completeness of the read-across. These factors here comprise the number of analogues, the 
absence/presence of toxicity, the quality of the underlying data for the source analogues, the 
consistency and concordance in the data and potency across the analogues including a 
consideration whether the temporal and dose response relationship between 
mechanistically relevant endpoints is consistent. For this uncertainty component, each 
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factor is weighted in the same grading scale as part of a weight of evidence assessment. The 
weight of evidence call reflects the overall uncertainty of the read-across itself. The grading 
scales used for the different parts of the uncertainty assessment are a modification of what 
Blackburn and Stuard [41] proposed as part of their own uncertainty assessment 
framework. Instead of 4 grades to the scheme, Schultz et al [25] have focused on 3 grades, 
the fourth had been a flag to indicate that a read-across was not appropriate because the 
uncertainty was too high.  
4.3 The ECHA Read-across Assessment Framework (RAAF) 
The ECHA RAAF [23] is intended to provide a framework and guidance for consistent 
evaluation of the scientific validity of a read-across. Although aimed at ECHA evaluators, it 
was published to assist industry registrants in developing their own read-across 
justifications when attempting to satisfy information required by making use of the 
adaptations in Annex XI of the REACH regulation [1]. The RAAF is structured to describe a 
number of different read-across scenarios. For each of these scenarios, a number of scientific 
considerations can be identified. Assessment elements are aligned with each consideration 
which carry over into an appraisal to inform decision making. There are 6 scenarios in total – two of these refer to analogue approaches, the other 4 are applicable to category 
approaches. There are 2 types of scenarios – one where the hypothesis is based on 
(bio)transformation to a common compound and the other where the hypothesis is based 
on different compounds having qualitatively similar properties. The only aspect that 
subcategorises these scenarios further, relates to whether there are quantitative variations 
in the properties observed across the category members. Hence, for the analogue approach 
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there are the same 2 read-across hypotheses. For a category approach, there are 4 scenarios 
to account for the fact that there may be quantitative variations for both read-across 
hypotheses. For each scenario, there comprises a pre-defined set of assessment elements 
(AEs) which are intended to cover all the essential scientific considerations that need to be 
addressed. Each assessment element is then scored from 1-5, where 5 is designated ǲacceptable with high confidenceǳ through to 1 which is not acceptable. These scores are 
termed assessment options (AOs). A minimum AO score of 3 – acceptable with sufficient 
confidence is needed for a read-across to be taken up and used to inform decision making. 
There are a number of common assessment elements – common since they are considered 
with any of the 6 scenarios as well as scenario specific elements. For example, a common 
assessment element might address the reliability and adequacy of the underlying analogue 
data. In contrast, a scenario specific assessment element might include: common underlying 
mechanism, exposure to other compounds than to those linked to the prediction as noted for 
analogue scenario 2 – different compounds have qualitatively similar properties. The 
outcome of the read-across assessment takes the form of a conclusion whereby the set of all 
individual AOs obtained for each of the AEs in the applied scenario are considered. Since all 
AEs are considered essential, all need to have a minimum AO of 3 or higher for the read-
across approach to be acceptable. The intention is that delineating the AEs in this manner 
with scores will facilitate an evaluator or indeed registrant to quickly identify the ǲweakest linkǳ in the read-across justification and help focus where additional evidence could be 
generated or collected to strengthen the justification. The type of ǲadditional evidenceǳ noted 
includes mechanistic information from in vitro, in chemico studies or in silico predictions as 
well as toxicokinetic data from in vivo or in vitro studies. The ECHA RAAF [22, 23] was 
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originally structured to address human health endpoints alone but has since been extended 
to capture environmental fate properties and environmental hazards as well as UVCBs 
(Substances of unknown or variable composition, complex reaction products or biological 
materials) [42].  
Table 3 compares and contrasts the selected read-across assessment frameworks. On the 
whole, all are quite similar to each other. The differences lie in the extent to which they are 
described and the extent to which the uncertainties once identified and evaluated might be 
addressed and reduced. The RAAF differs in terms of its level of prescription using the 
scenarios and the associated assessment elements. However, even these assessment 
elements bear much similarity to the similarity rationales described in the other 
frameworks. The only other difference in the RAAF is its intended purpose, a minimum score 
needs to be reached for any one assessment element in order to determine acceptance. The 
framework and considerations in Patlewicz et al [17] emphasise the practical means of how 
similarity rationales might be characterised and what additional data could be generated to 
reduce residual uncertainty [43]. As described earlier, the assessment frameworks provide 
strategies for characterising and dealing with potential sources of uncertainty in both the 
underlying data for the source analogues as well as the similarity considerations pertaining 
to the read-across itself. Some of the shortcomings of these approaches should still be noted, 
including the lack of strategies for integrating and evaluating different types of 
data/evidence (i.e. in vivo, versus in vitro versus, in silico) and their associated properties 
(i.e. strength, relevance, reliability, etc). Additional efforts are needed that draw from more 
established and systematic approaches for weighing evidence such as in the case of 
MoA/AOP-based risk assessment for which there is ample of literature and even technical 
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guidance documents [43-47] as well as new guidance that is evolving out of work from the 
OECD IATA case studies [12, 48-49]. 
 
Table 3: Comparison of the similarities and differences of selected read-across assessment 
frameworks
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Framework ECHA RAAF [23] Blackburn and 
Stuard [41] 
Patlewicz et al 
[17] 
Schultz et al [25] 
Context REACH Product 
Stewardship 
Regulatory 
purposes & 
Product 
stewardship 
Regulatory purposes & 
Product stewardship 
Scope Analogue/Category Analogue/Category 
 
Analogue/Category 
 
Analogue/Category 
 
Framework Scenarios addressing 
analogue (2) and 
category (4) approaches 
as described above 
Framework 
addresses 3 
aspects: analogue 
suitability 
(covered in [33]); 
Identifies the 
sources of 
uncertainty in 
relationship to the 
Different scenarios are 
articulated to frame up to 
11 different similarity 
criteria.  8 factors 
proposed to evaluate 
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Each scenario is 
associated with a 
number of assessment 
elements (AE) (both 
common and scenario 
specific).  
data quality of the 
analogues; 
consistency of the 
data across the 
analogues and 
relative to the 
target 
data and similarity 
context 
mechanistic relevance and 
completeness of the read-
across 
Data issues Characterised by 
common assessment 
elements 
No. of analogues, 
robustness of data, 
concordance of 
effects and 
potency, severity 
of critical effect 
No. of analogues, 
robustness of data, 
concordance of 
effects and 
potency, severity of 
critical effect 
No. of analogues, 
robustness of data, 
concordance of effects and 
potency, severity of critical 
effect which are then 
assessed as a WOE 
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Similarity 
rationales 
Characterised by 
scenario specific 
assessment elements 
Analogue 
suitability rating as 
described by Wu et 
al [33] 
Structural, 
physicochemical, 
reactivity, 
metabolic, 
toxicokinetic, and 
toxicological 
similarity 
(extended based on 
the considerations 
outlined and 
described in [20]) 
Structural, 
physicochemical, 
toxicokinetic, metabolic, 
structural alerts 
(reactivity), toxicological, 
mechanistic plausibility 
and AOP related events 
Grading 
scale 
Each AE is scored by an 
assessment option (AO) 
from 1-5. A minimum of 
3 must be achieved for 
Low – High 
gradings which are 
associated with 
default uncertainty 
None – possible 
strategies to 
reduce 
Low to High but no default 
quantitative uncertainty 
factors are proposed 
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all AEs for a given 
scenario for the read-
across to be acceptable. 
factors 1-10. High 
uncertainty 
translates to no 
read-across 
possible 
uncertainties are 
proposed 
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5. The need for a harmonised hybrid framework for read-across 
Given that there are many similarities between the frameworks discussed here, a 
harmonised framework could be readily proposed which integrates the similarity contexts, 
and sources of uncertainty from the existing frameworks. It is also worth highlighting one 
aspect that is missing from all the frameworks. Each of these frameworks is, to all extents, 
qualitative in nature and rely on expert input to evaluate a specific read-across assessment 
i.e. a read-across is typically performed on a case-by-case basis. There are only a couple of 
methodological aspects considered within the frameworks that are, to some extent, 
quantitative. For instance, the structural similarity search that is often employed by each of 
these development frameworks often relies upon a Tanimoto similarity (Jaccard coefficient) 
index as a numeric threshold to limit the number of plausible and pragmatic candidate 
source analogues. The data quality underpinning source analogues is often assessed using 
the principles outlined by Klimisch et al [50]. This is the standard used under EU regulatory 
schemes and results in a score on a scale of 1-4, where 1 is the highest quality and termed ǲreliable without restrictionǳ, ͵ is of lowest quality and termed ǲnot reliableǳ whereas Ͷ denotes ǲnot assignableǳ. However, there are no objective measures to assess the predictive 
performance of the read-across derived to demonstrate its general applicability nor any 
objective quantitative characterisation of the uncertainty associated with the prediction 
made. With regard to the latter, the confidence associated with a read-across prediction is at 
most assigned by an expert in terms of scores such as low, moderate or high on the basis of 
building up a body/weight of evidence. Blackburn and Stuard [41] proposed a grading 
scheme, which is characterised by specific criteria, but still relies on an expert driven 
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assessment of each component to determine a final uncertainty score and use of a specific 
uncertainty or assessment factor. This mirrors aspects of current and traditional risk 
assessment approaches which apply assessment factors to in vivo toxicity studies and use 
them as a basis to derive a reference value. Schultz et al [25] emphasised the need to build 
up a body/weight of evidence using data that characterise the different similarity contexts 
as well as the underlying toxicity data for the target and source analogues. However, the 
relative contribution or significance of any of these similarity contexts or underlying data in 
driving the overall confidence in the read-across is not well established in objective terms. 
In contrast, efforts by Low et al [4], examples highlighted in Zhu et al [7] and work by Shah 
et al [6] have explored the notion of quantifying read-across in a manner akin to approaches 
relied upon in QSAR. Specifically, in Shah et al [6], the focus was to systematically evaluate 
read-across performance and characterise its uncertainty for a large number of substances 
so that the approach could be generalisable and therefore capable of making inferences for 
large numbers of chemicals rather than require a manual and expert intervention on a case-
by-case basis. Further, recent work (Helman et al in prep; Pradeep et al [40]) has quantified 
the impact and role that other similarity contexts specifically physicochemical properties 
may play in driving read-across performance over and above chemical structural 
information alone. 
The harmonised framework proposed here is intended as a hybrid approach. The foundation 
of the harmonised framework is still anchored to the main steps of the current expert driven 
process taking into account insights and aspects captured in the other frameworks and 
refining current shortcomings such as exploiting systematic approaches to weighing 
evidence or strategies for integrating different types of data/evidence together. At the same 
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time, it exploits NAM and computational strategies to evolve read-across towards a more 
systematic, reproducible and objective approach i.e. exploring ways in which some read-
across aspects such as other contexts of similarity could be quantified where feasible or 
appropriate (Figure 9). Here the generic workflow in Patlewicz et al [26] has been used as a 
foundation to demonstrate the extensibility using the aspects captured in the other 
frameworks and highlighting where aspects of the read-across approach could be quantified, 
and where novel types of NAM information could be incorporated (Table 4).   
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Table 4: Harmonised hybrid framework for read-across incorporating aspects from all existing frameworks and introducing 
quantification of aspects of read-across where feasible 
Step Practical aspects Comments 
1.Decision context  Gauge the scope of the read-across 
assessment needed i.e. the level of effort and 
resources that might be required to 
undertake the read-across assessment 
workflow. Determine the type of read-
across prediction that might be feasible 
based on the underlying data (categorical or 
quantitative in nature) and sufficient for the 
different risk-decision contexts  
Regulatory contexts such as risk assessment in e.g. PPRTV 
and REACH [1], emergency response assessments. Other 
contexts might cover product stewardship, screening level 
assessment 
2.Data gap analysis Determine the number and type of data 
gaps for the target.  
Use this to determine whether a data gap filling strategy 
might be practically best addressed by other techniques. 
This might be appropriate for endpoints such as 
physicochemical properties, various ecotoxicity or 
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environmental fate properties for which QSARs are 
typically better established. For a single data gap such as 
for an endpoint which is reasonably well understood 
mechanistically or indeed has an associated AOP 
established, defined approaches might be better applied 
for data gap filling. Examples include oestrogenicity [47] 
where a battery of specific HTS assays are integrated into 
a prediction model or the defined approaches that have 
been developed to integrate multiple key event 
information together in a systematic objective manner for 
the skin sensitisation endpoint [48-49] 
For other endpoints or for a larger number of data gaps, 
continuing to step 3 of the workflow may be more 
appropriate. 
3.Overarching 
similarity rationale 
Perform an initial profiling of the target 
substance to explore the types of effects 
This could result in establishing which of the scenarios 
described in the RAAF [23] or those articulated by Schultz 
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observed, whether anything is known about 
the target organs, mechanisms of action or 
toxicokinetics to determine whether effects 
are likely to be driven by the target or its 
(abiotic, biotic, metabolic) transformation 
product. This profiling would ideally 
consider both available empirical data as 
well as those predicted effects using (Q)SAR 
to help inform the basis for how analogues 
should be identified to develop 
analogue/category approaches.  
et al [25] or the OECD grouping guidance itself [14] are 
most useful in driving the analogue identification step. 
4.Analogue 
identification 
Directed by the outcomes of the data gap 
analysis and overarching rationale steps. 
This could be as simple as performing a 
structure search using a similarity metric 
such as Tanimoto. It could also consider 
Scope includes category approaches where assessment of 
several category members and/or a several endpoints are 
of interest. 
Custom searches are described in Wu et al [33] and Wang 
et al [35]. 
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other similarity contexts such as 
physicochemical profiles or structural 
alerts etc. sequentially (search on one 
context and subcategorising the outcomes 
derived) or it could involve a Ǯsearch 
expansionǯ approach whereby a custom 
fingerprint of structural characteristics are 
weighted alongside a custom fingerprint of 
physicochemical characteristics, 
presence/absence of structural alerts, 
structural and topological features from a 
metabolic profiler, bioactivity fingerprint 
from HT/HC screening data to search for 
analogues objectively using a similarity 
index such as the Jaccard index  
Custom searches that might rely on chemical 
features/properties pertinent for a specific endpoint  
Objective Ǯsearch expansion5ǯ approaches as discussed by 
Helman et al (in prep).  
It is worth noting that grouping substances on the basis of 
NAM data such as HT/HC could also be an aim in itself – 
especially for other types of assessments e.g. efficacy 
assessments. 
 
                                         
5 In Helman et al (in prep) – approaches for searching for similar analogues on the basis of structural and physicochemical characteristics at the same 
time were described as a search expansion approach 
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5.Analogue 
evaluation 
Underlying data and analogue evaluation. 
Addresses the similarity contexts if not 
considered explicitly in the analogue 
identification step. Codify the data quality 
using schemes such as Klimisch et al [50] 
and quantity the data variability if multiple 
studies from the same endpoint are 
available or apply a global variability factor. 
Focus on consistency and concordance in 
effects and potency as well as their 
temporal and dose response relationship 
across analogues and endpoints and 
relative to the target. 
This is described in more detail in Schultz et al [25] and to 
an extent Blackburn and Stuard [41]. Boxplot analysis may 
aid in comparing variability of data across multiple studies 
for the same substance. 
Strategies to understand the role and impact that these 
different similarity contexts have in driving the 
endpoint(s) of interest and the performance of the 
associated read-across are needed. Progress has been 
made in Helman et al (in prep) for physicochemical 
similarity. 
Approaches to evaluate the weight of evidence (WOE) 
from the different source analogues to codify and to an 
extent quantify their relative contribution to the read-
across required are also needed. Efforts have been made 
in clarifying an quantifying WOE approaches (see [45-46])   
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6.Data gap filling Quantitative or qualitative read-across. 
Most sensitive value, average, similarity 
weighted average, other approaches. 
This could include both data driven (machine learning, 
Bayesian inference) and expert driven means to derive a 
prediction 
 
7.Uncertainty 
assessment 
Apply qualitative grading schemes as 
described in the RAAF [23], Schultz et al 
[25] or Blackburn and Stuard [41]. 
Apply quantitative assessment techniques 
which could borrow from decision theory 
relying on Weight of Evidence Bayesian 
approaches or QSAR approaches to include 
Area under the Curve (AUC) from a Receiver 
Operating Characteristic (ROC) curve or 
root mean square error (RMSE) from 
regression based prediction models. Both 
approaches are intended to quantify 
Feedback loop to assess whether the uncertainty exceeds 
what is needed for the overall decision context. 
Strategies to reduce uncertainties could include targeted 
generation of new data based on Ǯvalue of informationǯ or 
sensitivity analysis. Type of data that could be generated 
may include NAM information such as HT data anchored 
to specific pathways or AOPs.  
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performance using appropriate metrics and 
provide a quantitative measure of 
confidence for the read-across predictions 
made 
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6. Conclusions 
There are many frameworks and workflows described for both the development of read-
across and their assessment. Here a comparison has been made of a selection of the most 
well-established read-across frameworks (development and assessment) that have either 
been published as technical regulatory guidance or in the peer reviewed literature. We 
compared and contrasted their similarities and differences and proposed a harmonised 
hybrid framework that integrates all the different insights together. All the frameworks are 
(mainly) qualitative in nature and rely on expert judgement in both the development and 
assessment of a read-across. We highlighted how objective measures of performance 
assessment, evaluation of data variability and quantitative measures of similarity addressing 
many different contexts of similarity could be potentially brought to bear in aspects of the 
read-across framework. Doing so would help bridge the continuum between QSAR and read-
across and thus promote consistent reproducible predictions that can be fit for different 
decision contexts and purposes. 
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Disclaimer The views expressed in this article are those of the authors and do not necessarily 
reflect the views or policies of the U.S. Environmental Protection Agency. Mention of trade 
names or commercial products does not constitute endorsement or recommendation for use.   
60 
 
References 
[1] European Commission (EC), Regulation (EC) No 1907/2006 of the European Parliament 
and of the Council of 18 December 2006 concerning the Registration, Evaluation, 
Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals 
Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 
and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and 
Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. Off. J. Eur. 
Union L396/1 (2006).  
[2] EC – European Commission, Regulation (EC) No 1272/2008 of the European Parliament 
and of the Council of 16 December 2008 on classification, labelling and packaging of 
substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, 
and amending Regulation (EC) No 1907/2006. Off. J. Eur. Union L353/1 (2008). Commission 
of the European Communities. 
[3] EC- European Commission, Regulation (EC) No 1223/2009 of the European Parliament 
and the Council of 30 November 2009 on cosmetic products. Off. J. Eur. Union L342 (2009), 
59-209. 
[4] Y. Low, A. Sedykh, D. Fourches, A. Golbraikh, M. Whelan, I. Rusyn, A. Tropsha, Integrative 
chemical-biological read-across approach for chemical hazard classification, Chem. Res. 
Toxicol. 26 (2013) 1199-1208. 
[5] P. Pradeep, R.J. Povinelli, S.J. Merrill, S. Bozdag, D.S. Sem, Novel Uses of In Vitro Data to 
Develop Quantitative Biological Activity Relationship Models for in Vivo Carcinogenicity 
Prediction, Mol. Inf. 34 (2015) 236–245. https://doi.org/10.1002/minf.201400168 
61 
 
[6] I. Shah, J. Liu, R.S. Judson, R.S. Thomas, G. Patlewicz, Systematically evaluating read-across 
prediction and performance using a local validity approach characterized by chemical 
structure and bioactivity information, Regul. Toxicol. Pharmacol. 79 (2016) 12-24. 
https://doi.org/ 10.1016/j.yrtph.2016.05.008. 
[7] H. Zhu, M. Bouhifd, E. Donley, L. Egnash, N. Kleinstreuer, E.D. Kroese, Z. Liu, T. Luechtefeld, 
J. Palmer, D. Pamies, J. Shen, V. Strauss, S. Wu, T. Hartung, 2016. Supporting read-across using 
biological data, ALTEX 33 (2016) 167-182. https://doi.org/10.14573/altex.1601252. 
[8] T.W. Schultz, M.T.D Cronin, Lessons learned from read-across case studies for repeated-
dose toxicity, Regul. Toxicol. Pharmacol. 88 (2017) 185-191. 
https://doi.org/10.1016/j.yrtph.2017.06.011.  
[9] D.L. Villeneuve, D. Crump, N. Garcia-Reyero, M. Hecker, T.H. Hutchinson, C.A. LaLone, B. 
Landesmann, T. Lettieri, S. Munn, M. Nepelska, M.A. Ottinger, L. Vergauwen, M. Whelan, 2014. 
Adverse outcome pathway (AOP) development I: strategies and principles, Toxicol. Sci. 142 
(2014) 312-320. https://doi.org/10.1093/toxsci/kfu199. 
[10] S.W. Edwards, Y.M. Tan, D.L. Villeneuve, M.E. Meek, C.A. McQueen, Adverse Outcome 
Pathways-Organizing Toxicological Information to Improve Decision Making, J. Pharmacol. 
Exp. Ther. 356 (2016) 170-181. https://doi.org/10.1124/jpet.115.228239.  
[11] C. Wittwehr, H. Aladjov, G. Ankley, H.J. Byrne, J. de Knecht, E. Heinzle, G. Klambauer, B. 
Landesmann, M. Luijten, C. MacKay, G. Maxwell, M.E. Meek, A. Paini, E. Perkins, T. Sobanski, 
D. Villeneuve, K.M. Waters, M. Whelan, How Adverse Outcome Pathways Can Aid the 
Development and Use of Computational Prediction Models for Regulatory Toxicology, 
Toxicol. Sci. 155 (2017) 326-336. https://doi: 10.1093/toxsci/kfw207.  
62 
 
[12] OECD, Guidance Document for the Use of Adverse Outcome Pathways in Developing 
Integrated Approaches to Testing and Assessment (IATA) Series on Testing and Assessment 
No. 260. Organisation for Economic Co-operation and Development, Paris, France, 2017. 
[13] OECD, Guidance on grouping of chemicals. OECD Series on Testing and Assessment No. 
80. Organisation for Economic Co-operation and Development, Paris, France, 2007. 
[14] OECD, Guidance on grouping of chemicals. OECD Series on Testing and Assessment No. 
194. Organisation for Economic Co-operation and Development, Paris, France, 2014. 
[15] ECHA, Guidance on information requirements and chemical safety assessment. Chapter 
R.6: QSARs and grouping of chemicals, 2008. 
http://echa.europa.eu/documents/10162/13632/information_requirements_r6_en.pdf 
(accessed 9 April 2018). 
[16] G. Patlewicz, N. Ball, R.A. Becker, E.D. Booth, M.T.D.Cronin, D. Kroese, D. Steup, B. Van 
Ravenzwaay, T. Hartung, Food for thought….. Read-across approaches - misconceptions, 
promises and challenges ahead, ALTEX 31 (2014) 387-396. 
[17] G. Patlewicz, N. Ball, P. Boogaard, R.A. Becker, B. Hubesch, Building scientific confidence 
in the development and evaluation of read-across, Regul. Toxicol. Pharmacol. 72 (2015) 117-
133. 
[18] N. Ball, M.T. Cronin, J. Shen, K. Blackburn, E.D. Booth, M. Bouhifd, E. Donley, L. Egnash, C. 
Hastings, D.R. Juberg, A. Kleensang, N. Kleinstreuer, E.D. Kroese, A.C. Lee, T. Luechtefeld, A. 
Maertens, S. Marty, J.M. Naciff, J. Palmer, D. Pamies, M. Penman, A.N. Richarz, D.P. Russo, S.B. 
Stuard, G. Patlewicz, B. van Ravenzwaay, S. Wu, H. Zhu, T. Hartung, Toward Good Read-
63 
 
Across Practice (GRAP) guidance, ALTEX 33 (2016) 149-166. 
https://doi.org/10.14573/altex.1601251. 
[19] ECETOC, Technical Report 116 Category approaches, read-across, (Q)SAR. 
http://www.ecetoc.org/technical-reports, 2012 (accessed 9 April 2018) 
[20] G. Patlewicz, N. Ball, E.D. Booth, E. Hulzebos, E. Zvinavashe, C. Hennes, Use of category 
approaches, read-across and (Q)SAR: general considerations, Regul. Toxicol. Pharmacol. 67 
(2013) 1-12. https://doi.org/10.1016/j.yrtph.2013.06.002. 
[21] G. Patlewicz, D.W. Roberts, A. Aptula, K. Blackburn, B. Hubesch, Workshop: use of ǲread-acrossǳ for chemical safety assessment under REACH, Regul. Toxicol. Pharmacol. 65 (2013) 
226-228. https://doi.org/10.1016/j.yrtph.2012.12.004. 
[22] ECHA, Read-across Assessment Framework (RAAF). ECHA-15-R-07-EN, 2015. 
[23] ECHA, Read-Across Assessment Framework (RAAF) ECHA-17-R-01-EN, 2017. 
[24] E. Berggren, P. Amcoff, R. Benigni, K. Blackburn, E. Carney, M. Cronin, H. Deluyker, F. 
Gautier, R.S. Judson, G.E. Kass, D. Keller, D. Knight, W. Lilienblum, C. Mahony, I. Rusyn, T. 
Schultz, M. Schwarz, G. Schüürmann, A. White, J. Burton, A.M. Lostia, S. Munn, A. Worth, 
Chemical Safety Assessment Using Read-Across: Assessing the Use of Novel Testing Methods 
to Strengthen the Evidence Base for Decision Making, Environ. Health Perspect. 123 (2015) 
1232-1240. https://doi.org/10.1289/ehp.1409342. 
[25] T.W. Schultz, P. Amcoff, E. Berggren, F. Gautier, M. Kalric, D.J. Knight, C. Mahony, M. 
Schwarz, A. White, M.T.D. Cronin, A strategy for structuring and reporting a read-across 
prediction of toxicity, Regul. Toxicol. Pharmacol. 72 (2015) 586-601. 
64 
 
[26] G. Patlewicz, G. Helman, P. Pradeep, I. Shah, Navigating through the minefield of read-
across tools. A review of in silico tools for grouping, Computational Toxicology 3 (2017) 1-
18. 
[27] A.P. Worth, G. Patlewicz, A compendium of case studies that helped shape the REACH 
Guidance on Chemical Categories and Read-across, EUR 22481 EN, 2007. 
https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-
reports/compendium-case-studies-helped-shape-reach-guidance-chemical-categories-and-
read-across (accessed 9 April 2018).  
[28] G. Patlewicz, A. Gallegos Saliner, M. Pavan, A. Worth, R. Benigni, A. Aptula, A. Bassan, C. 
Bossa, A. Falk-Filipsson, V. Gillet, N. Jeliazkova, A. McDougal, J. Mestres, I. Munro, T. Netzeva, 
B. Safford, B. Simon-Hettich, I. Tsakovska, M. Wallen, C. Yang, Chemical Similarity and 
Threshold of Toxicological Concern (TTC) Approaches: Report of an ECB Workshop, EUR 
22657 EN, 2005 
https://pdfs.semanticscholar.org/7d68/8ba443aacfd1601e49f1452f3b1328117134.pdf 
(accessed 9 April 2018) 
[29] G Patlewicz, Chemical Categories and Read-across, EUR 21898EN, 2005 
https://core.ac.uk/download/pdf/38613756.pdf (accessed 9 April 2018) 
[30] R.H. Hanway, P.F.Evans, Read-across of toxicological data in the notification of new 
chemicals, Toxicol. Lett. 116 (Suppl. 1) (2000) 61. 
[31] US EPA, Data collection and development on high production volume (HPV) chemicals, 
Fed. Reg. 65 (248) (2000) 81686-81698. https://www.gpo.gov/fdsys/pkg/FR-2000-12-
26/pdf/00-32498.pdf (accessed 6 April 2018)  
65 
 
[32] OECD, Chapter 3: Data Evaluation in the Manual for the Assessment of Chemicals, 2000. 
http://www.oecd.org/chemicalsafety/risk-
assessment/manualfortheassessmentofchemicals.htm (accessed 6 April 2018) 
[33] S. Wu, K. Blackburn, J. Amburgey, J. Jaworska, T. Federle, A framework for using 
structural, reactivity, metabolic and physicochemical similarity to evaluate the suitability of 
analogs for SAR-based toxicological assessments, Regul. Toxicol. Pharmacol. 56 (2010) 67-
81. https://doi.org/10.1016/j.yrtph.2009.09.006. 
[34] K. Blackburn, D. Bjerke, G. Daston, S. Felter, C. Mahony, J. Naciff, S. Robison, S. Wu, Case 
studies to test: A framework for using structural, reactivity, metabolic and physicochemical 
similarity to evaluate the suitability of analogs for SAR-based toxicological assessments, 
Regul. Toxicol. Pharmacol. 60 (2011) 120-135. https:// 
doi.org/10.1016/j.yrtph.2011.03.002. 
[35] N.C. Wang, Q. Jay Zhao, S.C. Wesselkamper, J.C. Lambert, D. Petersen, J.K. Hess-Wilson, 
Application of computational toxicological approaches in human health risk assessment. I. A 
tiered surrogate approach, Regul. Toxicol. Pharmacol. 63 (2012) 10-19. 
https://doi.org/10.1016/j.yrtph.2012.02.006.  
[36] OECD, The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent 
Binding to Proteins Part 1: Scientific Evidence. Series on Testing and Assessment No. 168 
ENV/JM/MONO(2012)10/PART1, 2012. 
[37] S.D. Dimitrov, R. Diderich, T. Sobanski, T.S. Pavlov, G.V. Chankov, A.S. Chapkanov, Y.H. 
Karakolev, S.G. Temelkov, R.A. Vasilev, K.D. Gerova, C.D. Kuseva, N.D. Todorova, A.M. 
66 
 
Mehmed, M. Rasenberg, O.G. Mekenyan, QSAR Toolbox - workflow and major functionalities, 
SAR QSAR Environ. Res. 19 (2016) 1-17. 
[38] US EPA, Status and Future Directions of the High Production Volume Challenge Program. 
https://nepis.epa.gov/Exe/tiff2png.cgi/P1004QXK.PNG?-r+75+-
g+7+D%3A%5CZYFILES%5CINDEX%20DATA%5C00THRU05%5CTIFF%5C00001370%5C
P1004QXK.TIF, 2004 (access 6 April 2018) 
[39] P. Willett, J. Barnard, G. Downs, Chemical similarity searching, J. Chem. Inf. Comput. Sci. 
38 (1998) 983–996. 
[40] P. Pradeep, K. Mansouri, G. Patlewicz, R.S. Judson, A systematic evaluation of analogs 
and automated read-across prediction of estrogenicity: A case study using hindered phenols, 
Computational Toxicology 4 (2017) 22-30. 
[41] K. Blackburn, S.B. Stuard, A framework to facilitate consistent characterization of read 
across uncertainty, Regul. Toxicol. Pharmacol. 68 (2014) 353-362. 
[42] ECHA, Read-Across Assessment Framework (RAAF) - considerations on multi-
constituent substances and UVCBs, ECHA-17-R-04-EN, 2017. 
[43] US EPA, Guidelines for Carcinogen Risk Assessment. EPA/630/P-03/001F, 2005. 
https://www.epa.gov/sites/production/files/2013-
09/documents/cancer_guidelines_final_3-25-05.pdf (accessed 6 April 2018)  
[44] ECHA, Guidance on information requirements and chemical safety assessment Chapter 
R.4: Evaluation of available information, 2008. 
67 
 
http://echa.europa.eu/documents/10162/13632/information_requirements_r4_en.pdf 
(accessed 6 April 2018) 
[45] R.A. Becker, G.T. Ankley, S.W. Edwards, S.W. Kennedy, I. Linkov, B. Meek, M. Sachana, H. 
Segner, B. Van Der Burg, D.L. Villeneuve, H. Watanabe, T.S. Barton-Maclaren, Increasing 
Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill 
Considerations for Evaluating Weight of Evidence, Regul. Toxicol. Pharmacol. 72 (2015) 514-
537. https://doi.org/ 10.1016/j.yrtph.2015.04.004.  
[46] R.A. Becker, V. Dellarco, J. Seed, J.M. Kronenberg, B. Meek, J. Foreman, C. Palermo, C. 
Kirman, I. Linkov, R. Schoeny, M. Dourson, L.H. Pottenger, M.K. Manibusan, Quantitative 
weight of evidence to assess confidence in potential modes of action, Regul. Toxicol. 
Pharmacol. 86 (2017) 205-220. https://doi.org/10.1016/j.yrtph.2017.02.017.  
[47] E. Julien, A.R. Boobis, S.S. Olin, Ilsi Research Foundation Threshold Working Group. The 
key events dose–response framework: a cross-disciplinary mode-of-action based approach 
to examining dose–response and thresholds, Crit. Rev. Food Sci. Nutr. 49 (2009) 682-689. 
https://doi.org/10.1080/10408390903110692 
[48] OECD, Guidance Document for the Use of Adverse Outcome Pathways in Developing 
IATA. STA No. 260, ENV/JM/MONO(2016)67, Paris, France, 2016. 
[49] OECD, OECD Guidance Document on the Reporting of Defined Approaches (DAs) to Be 
Used within IATA. STA No. 255, ENV/JM/MONO(2016)28, Paris, France, 2016. 
68 
 
[50] H.J. Klimisch, M. Andreae, U. Tillmann, A systematic approach for evaluating the quality 
of experimental toxicological and ecotoxicological data, Regul. Toxicol. Pharmacol. 25 (1997) 
1-5. 
[51] R.S. Judson, F.M. Magpantay, V. Chickarmane, C. Haskell, N. Tania, J. Taylor, M. Xia, R. 
Huang, D.M. Rotroff, D.L. Filer, K.A. Houck, M.T. Martin, N. Sipes, A.M. Richard, K. Mansouri, 
R.W. Setzer, T.B. Knudsen, K.M. Crofton, R.S. Thomas, Integrated Model of Chemical 
Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays 
for the Estrogen Receptor, Toxicol Sci. 148 (2015) 137-154. 
https://doi.org/10.1093/toxsci/kfv168.  
  
69 
 
Figure 1: Graphical guide to the organisation of the manuscript 
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Figure 2: ECHA workflow for the analogue approach (taken from [15]) 
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Figure 3: ECHA stepwise workflow for the category approach (taken from [15]) 
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Figure 4: OECD workflows for analogue and category approaches [14]. Republished with 
permission of OECD, from Guidance on Grouping of Chemicals, Second Edition, 2014; permission 
conveyed through Copyright Clearance Center, Inc. 
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Figure 5: Overall approach by Wu et al [33]. Reprinted from Regulatory Toxicology and 
Pharmacology, 56, Wu et al., A framework for using structural, reactivity, metabolic and 
physicochemical similarity to evaluate the suitability of analogs for SAR-based toxicological 
assessments, pages 67-81, Copyright (2010), with permission from Elsevier 
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Figure 6: Analogue evaluation workflow described in Wu et al [33]. Reprinted from Regulatory 
Toxicology and Pharmacology, 56, Wu et al., A framework for using structural, reactivity, metabolic and 
physicochemical similarity to evaluate the suitability of analogs for SAR-based toxicological 
assessments, pages 67-81, Copyright (2010), with permission from Elsevier 
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Figure 7: Workflow described in Wang et al [35]. Reprinted from Regulatory Toxicology and 
Pharmacology, 63, Wang et al., Application of computational toxicological approaches in 
human health risk assessment. I. A tiered surrogate approach, pages 10-19, Copyright (2012), 
with permission from Elsevier 
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Figure 8: Workflow described by Patlewicz et al [17, 20] 
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Figure 9: A Harmonised Hybrid Development and Assessment Framework 
 
 
 
 
